Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.

Animals Antibodies, Monoclonal / immunology Antibodies, Neutralizing / immunology Antibodies, Viral / immunology Chlorocebus aethiops Cross Reactions Dengue / immunology Dengue Virus Epitope Mapping Female Flavivirus / metabolism Humans Immunoglobulin G / chemistry Inhibitory Concentration 50 Mice Mice, Inbred BALB C Mice, Inbred C57BL Protein Binding Protein Domains Tissue Donors Vaccination Vaccines, Inactivated / therapeutic use Vero Cells Viral Vaccines / therapeutic use Viremia Zika Virus Zika Virus Infection / immunology

Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
02 2020
Historique:
received: 18 01 2019
accepted: 18 12 2019
pubmed: 6 2 2020
medline: 22 4 2020
entrez: 5 2 2020
Statut: ppublish

Résumé

Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs.

Identifiants

DOI: 10.1038/s41591-019-0746-2 PMID: 32015557 PMC: PMC7018608
pubmed: 32015557
doi: 10.1038/s41591-019-0746-2
pii: 10.1038/s41591-019-0746-2
pmc: PMC7018608
mid: NIHMS1546987
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Immunoglobulin G 0
Vaccines, Inactivated 0
Viral Vaccines 0

Types de publication

Clinical Trial, Phase I Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

228-235

Subventions

Organisme : Intramural NIH HHS
ID : ZIA AI005143
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201000021C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201300021I
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 AI999999
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201300021C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201000021I
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI108568
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI114381
Pays : United States
Organisme : BLRD VA
ID : I01 BX003714
Pays : United States
Organisme : NIGMS NIH HHS
ID : P41 GM103403
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400058C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001102
Pays : United States

Références

Barouch, D. H., Thomas, S. J. & Michael, N. L. Prospects for a Zika virus vaccine. Immunity 46, 176–182 (2017).
pubmed: 28228277 pmcid: 28228277
Morabito, K. M. & Graham, B. S. Zika virus vaccine development. J. Infect. Dis. 216, S957–S963 (2017).
pubmed: 29267918 pmcid: 29267918
Pierson, T. C. & Diamond, M. S. The emergence of Zika virus and its new clinical syndromes. Nature 560, 573–581 (2018).
pubmed: 30158602 pmcid: 30158602
Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129–1132 (2016).
pubmed: 27492477 pmcid: 27492477
Abbink, P. et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci. Transl. Med. 9, eaao4163 (2017).
pubmed: 5747972 pmcid: 5747972
Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474–478 (2016).
pubmed: 5003703 pmcid: 5003703
Modjarrad, K. et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391, 563–571 (2018).
pubmed: 29217375 pmcid: 29217375
Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112–124 (2008).
Liao, H. X. et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 158, 171–179 (2009).
pubmed: 19428587 pmcid: 19428587
Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010).
pubmed: 20616233 pmcid: 20616233
Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55–62 (2014).
pubmed: 24590074 pmcid: 24590074
Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48–53 (2016).
pubmed: 27338953 pmcid: 27338953
Zhao, H. et al. Structural basis of Zika virus-specific antibody protection. Cell 166, 1016–1027 (2016).
pubmed: 27475895 pmcid: 27475895
Wang, J. et al. A human bi-specific antibody against Zika virus with high therapeutic potential. Cell 171, 229–241 (2017).
pubmed: 5673489 pmcid: 5673489
Robbiani, D. F. et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 169, 597–609 (2017).
pubmed: 5492969 pmcid: 5492969
Chappel, M. S. et al. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc. Natl Acad. Sci. USA 88, 9036–9040 (1991).
pubmed: 1833770 pmcid: 1833770
Davidson, E. & Doranz, B. J. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology 143, 13–20 (2014).
pubmed: 24854488 pmcid: 24854488
Sirohi, D. et al. The 3.8 Å resolution cryo-EM structure of Zika virus. Science 352, 467-–4470 (2016).
pubmed: 4845755 pmcid: 4845755
Cockburn, J. J. et al. Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J. 31, 767–779 (2012).
pubmed: 22139356 pmcid: 22139356
Robinson, L. N. et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell 162, 493–504 (2015).
pubmed: 4758460 pmcid: 4758460
Renner, M. et al. Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. Nat. Immunol. 19, 1248–1256 (2018).
Men, R. et al. Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus. J. Virology 78, 4665–4674 (2004).
pubmed: 15078949 pmcid: 15078949
Gentry, M. K., Henchal, E. A., McCown, J. M., Brandt, W. E. & Dalrymple, J. M. Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am. J. Trop. Med. Hyg. 31, 548–555 (1982).
pubmed: 6177259 pmcid: 6177259
Dai, L. et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 19, 696–704 (2016).
pubmed: 27158114 pmcid: 27158114
Lu, X. et al. Double lock of a human neutralizing and protective monoclonal antibody targeting the yellow fever virus envelope. Cell Rep. 26, 438–446 e435 (2019).
pubmed: 30625326 pmcid: 30625326
Rodriguez-Barraquer, I. et al. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science 363, 607–610 (2019).
pubmed: 30733412 pmcid: 30733412
Henchal, E. A., Gentry, M. K., McCown, J. M. & Brandt, W. E. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am. J. Trop. Med. Hyg. 31, 830–836 (1982).
pubmed: 6285749 pmcid: 6285749
Ye, J., Ma, N., Madden, T. L. & Ostell, J. M. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 41, W34–W40 (2013).
pubmed: 23671333 pmcid: 23671333
Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170–177 (2015).
pubmed: 25501631 pmcid: 25501631
Wang, Q. et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci. Transl. Med. 8, 369ra179 (2016).
pubmed: 27974667 pmcid: 27974667
Gallichotte, E. N. et al. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio 6, e01461–01415 (2015).
pubmed: 26463165 pmcid: 26463165
Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443–447 (2016).
pubmed: 27819683 pmcid: 27819683
Cox, K. S. et al. Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures. MAbs 8, 129–140 (2016).
pubmed: 26491897 pmcid: 26491897
Thomas, S. J. et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am. J. Trop. Med. Hyg. 88, 73–88 (2013).
pubmed: 23208878 pmcid: 23208878
Commo, F. & Bot, B.M. nplr: N-parameter logistic regression. Version 0.1-7 https://CRAN.R-project.org/package=nplr (2016).
McCracken, M. K. et al. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. PLoS Pathog. 13, e1006487 (2017).
pubmed: 5542404 pmcid: 5542404
Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. & Parren, P. W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virology 75, 12161–12168 (2001).
pubmed: 11711607 pmcid: 11711607
Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
pubmed: 2483472 pmcid: 2483472
Strong, M. et al. Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 8060–8065 (2006).
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010).
Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007).
Klungthong, C. et al. Monitoring and improving the sensitivity of dengue nested RT-PCR used in longitudinal surveillance in Thailand. J. Clin. Virol. 63, 25–31 (2015).
pubmed: 25600599 pmcid: 25600599

Auteurs

Vincent Dussupt (V)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
ORCID: 0000-0002-8579-6356

Rajeshwer S Sankhala (RS)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Gregory D Gromowski (GD)

Viral Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Gina Donofrio (G)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Rafael A De La Barrera (RA)

Pilot Bioproduction Facility, Center for Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Rafael A Larocca (RA)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ragon Institute of MGH, Cambridge, MA, USA.
ORCID: 0000-0002-9995-1804

Weam Zaky (W)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Letzibeth Mendez-Rivera (L)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Misook Choe (M)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Edgar Davidson (E)

Integral Molecular, Philadelphia, PA, USA.

Michael K McCracken (MK)

Viral Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

James D Brien (JD)

Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, USA.
ORCID: 0000-0002-1670-8041

Peter Abbink (P)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ragon Institute of MGH, Cambridge, MA, USA.
ORCID: 0000-0003-1978-088X

Hongjun Bai (H)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Aubrey L Bryan (AL)

Integral Molecular, Philadelphia, PA, USA.

Candace Hope Bias (CH)

Pilot Bioproduction Facility, Center for Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
ORCID: 0000-0002-4705-6947

Irina Maljkovic Berry (IM)

Viral Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
ORCID: 0000-0001-8555-5352

Nubia Botero (N)

Pilot Bioproduction Facility, Center for Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Tanya Cook (T)

Pilot Bioproduction Facility, Center for Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Nicole A Doria-Rose (NA)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Ariadna Grinyo I Escuer (AGI)

Integral Molecular, Philadelphia, PA, USA.

Justice Akuoku Frimpong (JA)

U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.

Aviva Geretz (A)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Mayda Hernandez (M)

Integral Molecular, Philadelphia, PA, USA.

Bradley S Hollidge (BS)

U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.

Ningbo Jian (N)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Kareem Kabra (K)

Pilot Bioproduction Facility, Center for Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
ORCID: 0000-0002-1955-5239

David J Leggat (DJ)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Jinyan Liu (J)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ragon Institute of MGH, Cambridge, MA, USA.

Amelia K Pinto (AK)

Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, USA.
ORCID: 0000-0002-7147-3978

Wiriya Rutvisuttinunt (W)

Viral Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Ian Setliff (I)

Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
ORCID: 0000-0003-4726-6132

Ursula Tran (U)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Samantha Townsley (S)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Benjamin J Doranz (BJ)

Integral Molecular, Philadelphia, PA, USA.

Morgane Rolland (M)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Adrian B McDermott (AB)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Ivelin S Georgiev (IS)

Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.

Rasmi Thomas (R)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
ORCID: 0000-0002-2116-2418

Merlin L Robb (ML)

U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Kenneth H Eckels (KH)

Pilot Bioproduction Facility, Center for Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Elizabeth Barranco (E)

Ponce Health Sciences University, CAIMED Center, Ponce, Puerto Rico, USA.

Michael Koren (M)

Viral Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Darci R Smith (DR)

U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
Immunodiagnostics Department, Biological Defense Research Directorate, Naval Medical Research Center, Fort Detrick, MD, USA.

Richard G Jarman (RG)

Viral Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
ORCID: 0000-0002-5765-0173

Sarah L George (SL)

Department of Internal Medicine, Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine and St Louis VA Medical Center, Saint Louis, MO, USA.

Kathryn E Stephenson (KE)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ragon Institute of MGH, Cambridge, MA, USA.

Dan H Barouch (DH)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ragon Institute of MGH, Cambridge, MA, USA.

Kayvon Modjarrad (K)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Nelson L Michael (NL)

Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

M Gordon Joyce (MG)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA. gjoyce@eidresearch.org.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA. gjoyce@eidresearch.org.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. gjoyce@eidresearch.org.
ORCID: 0000-0002-6808-7232

Shelly J Krebs (SJ)

Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA. skrebs@hivresearch.org.
U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA. skrebs@hivresearch.org.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. skrebs@hivresearch.org.
ORCID: 0000-0003-1136-1760

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Cercopithecus › Cercopithecus aethiops › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Phénomènes du système immunitaire › Réaction antigène-anticorps › Réactions croisées › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Fièvres hémorragiques virales › Dengue › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Flaviviridae › Flavivirus › Virus de la dengue › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Techniques d'investigation › Techniques de sonde moléculaire › Cartographie d'interactions entre protéines › Cartographie épitopique › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Flaviviridae › Flavivirus › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Concentration inhibitrice 50 › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Structure tertiaire des protéines › Domaines protéiques › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Personnes › Donneurs de tissus › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins inactivés › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules Vero › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Virémie › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Flaviviridae › Flavivirus › Virus Zika › Potent Zika and dengue cross-neutralizing...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Flaviviridae › Infections à flavivirus › Infection par le virus Zika › Potent Zika and dengue cross-neutralizing...